# US 2022/0089750 A1 · Car-expressing cells against multiple tumor antigens and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0089750 A1
- Document ID: US20220089750A1
- Status: Published application
- Kind: A1
- Application number: 17/489,674
- Filed: 2021-09-29
- Published: 2022-03-24
- Earliest claimed: 2015-02-02
- Assignees: Novartis AG; The Trustees of the University of Pennsylvania
- Applicants: Novartis AG; The Trustees of the University of Pennsylvania
- Inventors: Carl H. June; Daniel J. Powell, JR.
- Web page: https://patentgrep.com/patent/US20220089750A1

## CPC

- A61P 35/00: Antineoplastic agents
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/32: T-cell receptors [TCR]
- A61K 40/4202: {Receptors, cell surface antigens or cell surface determinants}
- A61K 40/4204: {Epidermal growth factor receptors [EGFR]}
- A61K 40/4205: {Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4}
- A61K 40/4211: {CD19 or B4}
- A61K 40/4255: {Mesothelin [MSLN]}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07K 14/54: Interleukins [IL]
- C07K 14/5418: {IL-7}
- C07K 14/5443: {IL-15}
- C07K 14/55: IL-2
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70521: {CD28, CD152}
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/30: from tumour cells
- C07K 16/32: against translation products of oncogenes
- C12N 5/0636: {T lymphocytes}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/58: Prostate
- A61K 2239/59: Reproductive system, e.g. uterus, ovaries, cervix or testes
- C07K 2317/22: from camelids, e.g. camel, llama or dromedary
- C07K 2317/31: multispecific
- C07K 2317/55: Fab or Fab'
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/00: Fusion polypeptide
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/531: Stem-loop; Hairpin
- C12N 2510/00: Genetically modified cells
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention provides compositions and methods for treating cancer by using immune effector cells (e.g., T cells, NK cells) engineered to conditionally express an agent which enhances the immune effector response of an immune effector cell that expresses a Chimeric Antigen Receptor (CAR). The conditional agents described herein include agents that target a cancer associated antigen, e.g., a CAR, agents that inhibit one or more checkpoint inhibitors of the immune response, and a cytokine.

## Claims

### Claim 1

An isolated nucleic acid, comprising:
(a) a nucleotide sequence encoding an agent, wherein the agent is a polypeptide or nucleic acid that enhances the immune response against a target cell or a cancer cell, wherein the agent is chosen from a chimeric antigen receptor (first CAR), an inhibitor of a checkpoint inhibitor, or a cytokine; and
(b) a first activation-conditional control region operatively linked to (a).

### Claim 2 (depends on 1)

The isolated nucleic acid of claim 1, further comprising:
(c) a nucleotide sequence encoding a second agent, wherein the second agent comprises a polypeptide or nucleic acid, that enhances the immune response against a target cell or a cancer cell, wherein the second agent is a CAR (second CAR); and
(d) a second control region operatively linked to (c), wherein the second control region is other than an activation-conditional control region or the second control region comprises a constitutive control region.

### Claim 3

An isolated nucleic acid comprising:
(a) a nucleotide sequence encoding an agent, wherein the agent is a polypeptide or nucleic acid that enhances the immune response against a target cell, or a cancer cell, and wherein the agent is chosen from a chimeric antigen receptor (first CAR), an inhibitor of a checkpoint inhibitor, or a cytokine, wherein the first CAR comprises a first an antigen binding domain, a transmembrane domain, and an intracellular signaling domain;
(b) a first activation-conditional control region operatively linked to (a);
(c) a nucleotide sequence encoding a second CAR comprising a second antigen binding domain, a transmembrane domain, and an intracellular signaling domain; and
(d) a second control region operatively linked to (c), wherein the second control region is other than an activation-conditional control region and wherein the second control region comprises a constitutive control region.

### Claim 4 (depends on 3)

The isolated nucleic acid of claim 3, wherein the second control region comprises a constitutive control region, e.g., an elongation factor 1 alpha (EF1a) control region.

### Claim 5 (depends on 3)

The isolated nucleic acid of claim 3, wherein the first or second CARs comprise an antigen binding domain, a transmembrane domain, and an intracellular signaling domain, and wherein the antigen binding domain binds to a cancer associated antigen chosen from: mesothelin, EGFRvIII, TSHR, CD19, CD123, CD22, CD30, CD171, CS-1, CLL-1, CD33, GD2, GD3, BCMA, Tn Ag, prostate specific membrane antigen (PSMA), ROR1, FLT3, FAP, TAG72, CD38, CD44v6, CEA, EPCAM, B7H3, KIT, IL-13Ra2, interleukin-11 receptor a (IL-11Ra), PSCA, PRSS21, VEGFR2, LewisY, CD24, platelet-derived growth factor receptor-beta (PDGFR-beta), SSEA-4, CD20, Folate receptor alpha (FRa), ERBB2 (Her2/neu), MUC1, epidermal growth factor receptor (EGFR), NCAM, Prostase, PAP, ELF2M, Ephrin B2, IGF-I receptor, CAIX, LMP2, gp100, bcr-abl, tyrosinase, EphA2, Fucosyl GM1, sLe, GM3, TGS5, HMWMAA, o-acetyl-GD2, Folate receptor beta, TEM1/CD248, TEM7R, CLDN6, GPRC5D, CXORF61, CD97, CD179a, ALK, Polysialic acid, PLAC1, GloboH, NY-BR-1, UPK2, HAVCR1, ADRB3, PANX3, GPR20, LY6K, OR51E2, TARP, WT1, NY-ESO-1, LAGE-1a, MAGE-A1, legumain, HPV E6,E7, MAGE A1, ETV6-AML, sperm protein 17, XAGE1, Tie 2, MAD-CT-1, MAD-CT-2, Fos-related antigen 1, p53, p53 mutant, prostein, survivin and telomerase, PCTA-1/Galectin 8, MelanA/MART1, Ras mutant, hTERT, sarcoma translocation breakpoints, ML-IAP, ERG (TMPRSS2 ETS fusion gene), NA17, PAX3, Androgen receptor, Cyclin B1, MYCN, RhoC, TRP-2, CYP1B1, BORIS, SART3, PAX5, OY-TES1, LCK, AKAP-4, SSX2, RAGE-1, human telomerase reverse transcriptase, RU1, RU2, intestinal carboxyl esterase, mut hsp70-2, CD79a, CD79b, CD72, LAIR1, FCAR, LILRA2, CD300LF, CLEC12A, BST2, EMR2, LY75, GPC3, FCRL5, or IGLL1.

### Claim 6

(canceled)

### Claim 7 (depends on 5)

The isolated nucleic acid of claim 5, wherein the mesothelin binding domain comprises:
(i) a light chain complementary determining region 1 (LC CDR1), a light chain complementary determining region 2 (LC CDR2), and a light chain complementary determining region 3 (LC CDR3) of any mesothelin binding domain in Table 2; and a heavy chain complementary determining region 1 (HC CDR1), a heavy chain complementary determining region 2 (HC CDR2), and a heavy chain complementary determining region 3 (HC CDR3) of a mesothelin binding domain in Table 2;
(ii) the LC CDR1, LC CDR2, and LC CDR3 of the LC CDR sequences listed in Table 4; and the HC CDR1, HC CDR2, and HC CDR3 of the HC CDR sequences listed in Table 3;
(iii) an amino acid sequence of Table 2 chosen from SEQ ID NO: 51, SEQ ID NO: 57, SEQ ID NO: 70, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, or SEQ ID NO: 69; or
(iv) an amino acid sequence with at least 95-99% homology to an amino acid sequence provided in Table 2, chosen from SEQ ID NO: 51, SEQ ID NO: 57, SEQ ID NO: 70, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, or SEQ ID NO: 69.

### Claim at position 8

-13. (canceled)

### Claim 14 (depends on 3)

The isolated nucleic acid of claim 3, wherein:
(i) the first antigen and the second antigen are co-expressed on a cancer cell;
(ii) the first antigen is expressed on a first population of cancer cells and the second antigen is expressed on a second population of cancer cells; or
(iii) the second antigen is expressed on a cancer cell and wherein the first antigen is not expressed on the cancer cell.

### Claim at position 10

-16. (canceled)

### Claim 17 (depends on 3)

The isolated nucleic acid of claim 3, wherein:
(i) the first antigen is chosen from: Folate receptor alpha (FRa), ERBB2 (Her2/neu), EphA2, IL-13Ra2, epidermal growth factor receptor (EGFR), Mesothelin, TSHR, CD19, CD123, CD22, CD30, CD171, CS-1, CLL-1, CD33, EGFRvIII, GD2, GD3, BCMA, Tn Ag, prostate specific membrane antigen (PSMA), ROR1, FLT3, FAP, TAG72, CD38, CD44v6, CEA, EPCAM, B7H3, KIT, interleukin-11 receptor a (IL-11Ra), PSCA, PRSS21, VEGFR2, LewisY, CD24, platelet-derived growth factor receptor-beta (PDGFR-beta), SSEA-4, CD20, MUC1, NCAM, Prostase, PAP, ELF2M, Ephrin B2, IGF-I receptor, CAIX, LMP2, gp100, bcr-abl, tyrosinase, Fucosyl GM1, sLe, GM3, TGS5, HMWMAA, o-acetyl-GD2, Folate receptor beta, TEM1/CD248, TEM7R, CLDN6, GPRC5D, CXORF61, CD97, CD179a, ALK, Polysialic acid, PLAC1, GloboH, NY-BR-1, UPK2, HAVCR1, ADRB3, PANX3, GPR20, LY6K, OR51E2, TARP, WT1, NY-ESO-1, LAGE-1a, MAGE-A1, legumain, HPV E6,E7, MAGE A1, ETV6-AML, sperm protein 17, XAGE1, Tie 2, MAD-CT-1, MAD-CT-2, Fos-related antigen 1, p53, p53 mutant, prostein, survivin, telomerase, PCTA-1/Galectin 8, MelanA/MART1, Ras mutant, hTERT, sarcoma translocation breakpoints, ML-IAP, ERG (TMPRSS2 ETS fusion gene), NA17, PAX3, Androgen receptor, Cyclin B1, MYCN, RhoC, TRP-2, CYP1B1, BORIS, SART3, PAX5, OY-TES1, LCK, AKAP-4, SSX2, RAGE-1, human telomerase reverse transcriptase, RU1, RU2, intestinal carboxyl esterase, mut hsp70-2, CD79a, CD79b, CD72, LAIR1, FCAR, LILRA2, CD300LF, CLEC12A, BST2, EMR2, LY75, GPC3, FCRL5, or IGLL1; and/or
(ii) the second antigen is selected from the group consisting of: Mesothelin, EGFRvIII, TSHR, CD19, CD123, CD22, CD30, CD171, CS-1, CLL-1, CD33, EGFRvIII, GD2, GD3, BCMA, Tn Ag, prostate specific membrane antigen (PSMA), ROR1, FLT3, FAP, TAG72, CD38, CD44v6, CEA, EPCAM, B7H3, KIT, interleukin-11 receptor a (IL-11Ra), PSCA, PRSS21, VEGFR2, LewisY, CD24, platelet-derived growth factor receptor-beta (PDGFR-beta), SSEA-4, CD20, MUC1, NCAM, Prostase, PAP, ELF2M, Ephrin B2, IGF-I receptor, CAIX, LMP2, gp100, bcr-abl, tyrosinase, Fucosyl GM1, sLe, GM3, TGS5, HMWMAA, o-acetyl-GD2, Folate receptor alpha (FRa), ERBB2 (Her2/neu), EphA2, IL-13Ra2, epidermal growth factor receptor (EGFR), Folate receptor beta, TEM1/CD248, TEM7R, CLDN6, GPRC5D, CXORF61, CD97, CD179a, ALK, Polysialic acid, PLAC1, GloboH, NY-BR-1, UPK2, HAVCR1, ADRB3, PANX3, GPR20, LY6K, OR51E2, TARP, WT1, NY-ESO-1, LAGE-1a, MAGE-A1, legumain, HPV E6,E7, MAGE A1, ETV6-AML, sperm protein 17, XAGE1, Tie 2, MAD-CT-1, MAD-CT-2, Fos-related antigen 1, p53, p53 mutant, prostein, survivin, telomerase, PCTA-1/Galectin 8, MelanA/MART1, Ras mutant, hTERT, sarcoma translocation breakpoints, ML-IAP, ERG (TMPRSS2 ETS fusion gene), NA17, PAX3, Androgen receptor, Cyclin B1, MYCN, RhoC, TRP-2, CYP1B1, BORIS, SART3, PAX5, OY-TES1, LCK, AKAP-4, SSX2, RAGE-1, human telomerase reverse transcriptase, RU1, RU2, intestinal carboxyl esterase, mut hsp70-2, CD79a, CD79b, CD72, LAIR1, FCAR, LILRA2, CD300LF, CLEC12A, BST2, EMR2, LY75, GPC3, FCRL5, and IGLL1.

### Claim at position 12

-22. (canceled)

### Claim 23 (depends on 3)

The isolated nucleic acid of claim 3, wherein the transmembrane domain of the first and/or second CAR comprises:
(i) a transmembrane domain from a protein selected from the group consisting of the alpha, beta or zeta chain of the T-cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137 and CD154;
(ii) a transmembrane domain that comprises the amino acid sequence of SEQ ID NO: 12,
(iii) a transmembrane domain that comprises an amino acid sequence comprises at least one, two or three modifications but not more than 20, 10 or 5 modifications of the amino acid sequence of SEQ ID NO:12, or
(iv) a transmembrane domain that comprises a sequence with 95-99% identity to the amino acid sequence of SEQ ID NO:12.

### Claim 24

(canceled)

### Claim 25 (depends on 3)

The isolated nucleic acid of claim 3, wherein the antigen binding domain of the first and/or second CAR is connected to the transmembrane domain by a hinge region, wherein the hinge region comprises SEQ ID NO:4, or a sequence with 95-99% identity thereof.

### Claim 26

(canceled)

### Claim 27 (depends on 3)

The isolated nucleic acid of claim 3, wherein the intracellular signaling domain of the first and/or second CAR comprises a costimulatory signaling domain comprising:
(i) a functional signaling domain obtained from a protein chosen from a MHC class I molecule, a TNF receptor protein, an Immunoglobulin-like protein, a cytokine receptor, an integrin, a signaling lymphocytic activation molecule (SLAM protein), an activating NK cell receptor, BTLA, a Toll ligand receptor, OX40, CD2, CD7, CD27, CD28, CD30, CD40, CDS, ICAM-1, LFA-1 (CD11a/CD18), 4-1BB (CD137), B7-H3, CDS, ICAM-1, ICOS (CD278), GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8alpha, CD8beta, IL2R beta, IL2R gamma, IL7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, NKG2D, NKG2C, TNFR2, TRANCE/RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG/Cbp, CD19a, or a ligand that specifically binds with CD83;
(ii) the amino acid sequence of SEQ ID NO:14;
(iii) an amino acid sequence having at least one, two or three modifications but not more than 20, 10 or 5 modifications of the amino acid sequence of SEQ ID NO:14, or
(iv) an amino acid sequence with 95-99% identity to the amino acid sequence of SEQ ID NO:14.

### Claim 28

(canceled)

### Claim 29 (depends on 3)

The isolated nucleic acid of claim 3, wherein the intracellular signaling domain comprises:
(i) a functional signaling domain of 4-1BB and/or a functional signaling domain of CD3 zeta;
(ii) the amino acid sequence of SEQ ID NO: 14 and/or the amino acid sequence of SEQ ID NO:18 or SEQ ID NO:20; or an amino acid sequence having at least one, two or three modifications but not more than 20, 10 or 5 modifications of the amino acid sequence of SEQ ID NO:14 and/or the amino acid sequence of SEQ ID NO:18 or SEQ ID NO:20; or an amino acid sequence with 95-99% identity to the amino acid sequence of SEQ ID NO:14 and/or the amino acid sequence of SEQ ID NO:18 or SEQ ID NO:20; or
(iii) the amino acid sequence of SEQ ID NO:14 and the amino acid sequence of SEQ ID NO:18 or SEQ ID NO:20, wherein the amino acid sequences comprising the intracellular signaling domain are expressed in the same frame and as a single polypeptide chain.

### Claim at position 20

-32. (canceled)

### Claim 33 (depends on 3)

The isolated nucleic acid of claim 3, wherein the first CAR comprises:
(i) the amino acid sequence of: an amino acid sequence in Table 7, the amino acid sequence of SEQ ID NO: 150, or the amino acid sequence of SEQ ID NO: 152;
(ii) an amino acid sequence having at least one, two or three modifications but not more than 30, 20 or 10 modifications to: an amino acid sequence in Table 7, the amino acid sequence of SEQ ID NO: 150, or the amino acid sequence of SEQ ID NO: 152;
(iii) an amino acid sequence with 95-99% identity to: an amino acid sequence in Table 7, the amino acid sequence of SEQ ID NO: 150, or the amino acid sequence of SEQ ID NO: 152;
(iv) a nucleic acid sequence in Table 7, the nucleic acid sequence of SEQ ID NO: 151 or the nucleic acid sequence of SEQ ID NO: 153; or
(v) a nucleic acid sequence with 95-99% identity to: a nucleic acid sequence in Table 7, or the nucleic acid sequence of SEQ ID NO: 151 or the nucleic acid sequence SEQ ID NO: 153.

### Claim 34

(canceled)

### Claim 35 (depends on 3)

The isolated nucleic acid claim 3, wherein the second CAR comprises:
(i) an amino acid sequence in Table 6chosen from SEQ ID NO: 104, SEQ ID NO: 110, SEQ ID NO: 124, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, or SEQ ID NO: 123;
(ii) an amino acid sequence having at least one, two or three modifications but not more than 30, 20 or 10 modifications to an amino acid sequence in Table 6, chosen from SEQ ID NO: 104, SEQ ID NO: 110, SEQ ID NO: 124, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, or SEQ ID NO: 123;
(iii) an amino acid sequence with 95-99% identity to an amino acid sequence in Table 6, chosen from SEQ ID NO: 104, SEQ ID NO: 110, SEQ ID NO: 124, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, or SEQ ID NO: 123;
(iv) a nucleic acid sequence in Table 6 chosen from SEQ ID NO: 129, SEQ ID NO: 135, SEQ ID NO: 149, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145, SEQ ID NO: 146, SEQ ID NO: 147, or SEQ ID NO: 148; or
(v) a nucleic acid sequence with 95-99% identity to a nucleic acid sequence in Table 6 chosen from SEQ ID NO: 129, SEQ ID NO: 135, SEQ ID NO: 149, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145, SEQ ID NO: 146, SEQ ID NO: 147, or SEQ ID NO: 148.

### Claim 36

(canceled)

### Claim 37 (depends on 3)

The isolated nucleic acid of claim 3, further comprising:
(e) a sequence encoding a third CAR; and/or,
(f) a second activation-conditional control region operatively linked to (e), wherein the activation-conditional control region is operatively linked to (f).

### Claim 38 (depends on 3)

The isolated nucleic acid of claim 3, wherein (a) comprises:
(i) a nucleotide sequence encoding an inhibitor of a checkpoint inhibitor of the immune response, wherein:
(a) the checkpoint inhibitor of the immune response is selected from the group consisting of: PD1, PD-L1, CTLA4, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, CD80, CD86, B7-H3 (CD276), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD270), KIR, A2aR, MHC class I, MHC class II, GALS, adenosine, and TGFR beta, or a combination thereof;
(b) the nucleotide sequence encodes an RNA-based inhibitor, e.g., an shRNA; or
(c) the nucleotide sequence encodes an antibody molecule; and/or
(ii) a nucleotide sequence encoding a cytokine, wherein the cytokine comprises IL-2, IL-7, IL-15, or IL-21.

### Claim at position 27

-43. (canceled)

### Claim 44 (depends on 3)

The isolated nucleic acid of claim 3, wherein the activation-conditional control region comprises:
(i) a nucleotide sequence that induces expression of (a) upon immune effector cell activation;
(ii) a promoter of a gene that is induced upon immune effector cell activation;
(iii) a nuclear factor of activated T cells (NFAT) promoter, an NF-kB promoter, an IL-2 promoter, or an IL-2 receptor (IL-2R) promoter;
(iv) one or more binding sites for a transcription modulator, e.g., a transcription factor, that induces gene expression upon immune effector cell activation;
(v) one or more NFAT binding sides;
(vi) comprises one or more sequences selected from GGAAA, GGGACT, SEQ ID NO: 261, or SEQ ID NO: 262.

### Claim at position 29

-49. (canceled)

### Claim 50 (depends on 3)

The isolated nucleic acid of claim 3, wherein the second control region that is other than an activation-conditional control region is a constitutive control region, wherein the constitutive control region comprises a constitutive promoter, an EF1alpha promoter, or the nucleic acid sequence of SEQ ID NO: 1.

### Claim at position 31

-53. (canceled)

### Claim 54 (depends on 3)

The isolated nucleic acid of claim 3, wherein:
(i) (a) and (b) are disposed on a single nucleic acid molecule, a viral vector, or a lentivirus vector; or (a) and (c) are disposed on a single nucleic acid molecule, a viral vector, or a lentivirus vector;
(ii) (a), (b), (c) and (d) are all disposed on a single nucleic acid molecule, a viral vector, or a lentivirus vector;
(iii) (a) is disposed on a first nucleic acid molecule, or a first viral vector, or a first lentivirus vector; and (c) is disposed on a second nucleic acid molecule, or a second viral vector, or a second lentivirus vector; or (a) and (b) are disposed on a first nucleic acid molecule, or a first viral vector or a first lentivirus vector; and (c) and (d) are disposed on a second nucleic acid molecule, or a second viral vector, or a second lentivirus vector;
(iv) the isolated nucleic acid comprises a bicistronic viral vector, or a bicistronic lentivirus vector; or
(v) (a) is translated as a first RNA and (c) is translated as a second RNA.

### Claim at position 33

-62. (canceled)

### Claim 63 (depends on 3)

A vector system comprising the isolated nucleic acid of claim 3.

### Claim 64 (depends on 3)

A cell or an immune effector cell comprising the isolated nucleic acid of claim 3, optionally wherein the cell is a human cell, a T cell, or an NK cell.

### Claim at position 36

-68. (canceled)

### Claim 69 (depends on 3)

A method of making a CAR cell, comprising introducing into a cell, the isolated nucleic acid of claim 3,
thereby making the CAR cell.

### Claim at position 38

-74. (canceled)

### Claim 75 (depends on 64)

A method of treating a subject having a cancer comprising administering to the subject an effective amount of the cell of claim 64,
thereby treating a subject.

### Claim at position 40

-82. (canceled)

### Claim 83 (depends on 75)

The method of claim 75, wherein the cancer is:
(i) associated with expression of a cancer associated antigen chosen from Mesothelin, TSHR, CD19, CD123, CD22, CD30, CD171, CS-1, CLL-1, CD33, EGFRvIII, GD2, GD3, BCMA, Tn Ag, prostate specific membrane antigen (PSMA), ROR1, FLT3, FAP, TAG72, CD38, CD44v6, CEA, EPCAM, B7H3, KIT, IL-13Ra2, interleukin-11 receptor a (IL-11Ra), PSCA, PRSS21, VEGFR2, LewisY, CD24, platelet-derived growth factor receptor-beta (PDGFR-beta), SSEA-4, CD20, Folate receptor alpha, ERBB2 (Her2/neu), MUC1, epidermal growth factor receptor (EGFR), NCAM, Prostase, PAP, ELF2M, Ephrin B2, IGF-I receptor, CAIX, LMP2, gp100, bcr-abl, tyrosinase, EphA2, Fucosyl GM1, sLe, GM3, TGS5, HMWMAA, o-acetyl-GD2, Folate receptor beta, TEM1/CD248, TEM7R, CLDN6, GPRC5D, CXORF61, CD97, CD179a, ALK, Polysialic acid, PLAC1, GloboH, NY-BR-1, UPK2, HAVCR1, ADRB3, PANX3, GPR20, LY6K, OR51E2, TARP, WT1, NY-ESO-1, LAGE-1a, MAGE-A1, legumain, HPV E6,E7, MAGE A1, ETV6-AML, sperm protein 17, XAGE1, Tie 2, MAD-CT-1, MAD-CT-2, Fos-related antigen 1, p53, p53 mutant, prostein, survivin and telomerase, PCTA-1/Galectin 8, MelanA/MART1, Ras mutant, hTERT, sarcoma translocation breakpoints, ML-IAP, ERG (TMPRSS2 ETS fusion gene), NA17, PAX3, Androgen receptor, Cyclin B1, MYCN, RhoC, TRP-2, CYP1B1, BORIS, SART3, PAX5, OY-TES1, LCK, AKAP-4, SSX2, RAGE-1, human telomerase reverse transcriptase, RU1, RU2, intestinal carboxyl esterase, mut hsp70-2, CD79a, CD79b, CD72, LAIR1, FCAR, LILRA2, CD300LF, CLEC12A, BST2, EMR2, LY75, GPC3, FCRL5, or IGLL1;
(ii) a solid cancer chosen from colon cancer, rectal cancer, renal-cell carcinoma, liver cancer, non-small cell carcinoma of the lung, cancer of the small intestine, cancer of the esophagus, melanoma, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, testicular cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, non-Hodgkin's lymphoma, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, solid tumors of childhood, cancer of the bladder, cancer of the kidney or ureter, carcinoma of the renal pelvis, neoplasm of the central nervous system (CNS), primary CNS lymphoma, tumor angiogenesis, spinal axis tumor, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid cancer, squamous cell cancer, T-cell lymphoma, environmentally induced cancers, or combinations of said cancers, and metastatic lesions of said cancers; or
(iii) a hematologic cancer chosen from one or more of chronic lymphocytic leukemia (CLL), acute leukemias, acute lymphoid leukemia (ALL), B-cell acute lymphoid leukemia (B-ALL), T-cell acute lymphoid leukemia (T-ALL), chronic myelogenous leukemia (CML), B cell prolymphocytic leukemia, blastic plasmacytoid dendritic cell neoplasm, Burkitt's lymphoma, diffuse large B cell lymphoma, follicular lymphoma, hairy cell leukemia, small cell- or a large cell-follicular lymphoma, malignant lymphoproliferative conditions, MALT lymphoma, mantle cell lymphoma, marginal zone lymphoma, multiple myeloma, myelodysplasia and myelodysplastic syndrome, non-Hodgkin's lymphoma, Hodgkin's lymphoma, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasm, Waldenstrom macroglobulinemia, or pre-leukemia.

### Claim at position 42

-85. (canceled)

### Claim 86 (depends on 75)

The method of claim 75, wherein the cell comprises a second CAR under control of a constitutive control region, and a first CAR under control of an activation-conditional control region, wherein the first CAR is expressed upon binding of the second CAR to a cancer associated antigen expressed on a cancer cell, optionally wherein:
(i) the second CAR comprises an antigen binding domain that binds to mesothelin; and the first CAR comprises an antigen binding domain that binds to FRa or ErbB2 (Her2/neu); or
(ii) the second CAR comprises an antigen binding domain that binds to EGFRvIII; and the first CAR comprises an antigen binding domain that binds to EGFR or other variants thereof, ErbB2 (Her2/neu), EphA2, or IL-13Ra2.

### Claim at position 44

-91. (canceled)

### Claim 92 (depends on 64)

A method of providing a CAR cell of claim 64, comprising:
(i) providing an immune effector cell or a T cell from a human, to a recipient entity, wherein the recipient entity is a laboratory or hospital; and
(ii) receiving from said entity, a CAR cell, derived from said immune effector cell, or a daughter cell thereof.

### Claim at position 46

-94. (canceled)

### Claim 95 (depends on 3)

A method of providing a CAR cell, comprising:
(i) receiving from an entity, or a health care provider, an immune effector cell, or a T cell, from a human;
(ii) inserting a nucleic acid of claim 3, into said immune effector cell, or a daughter cell thereof, to form the CAR cell; and/or
(iii) providing the cell to the entity.
